Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dyclonine + salbutamol is a combination medication that pairs a local anesthetic (dyclonine) with a bronchodilator (salbutamol). Dyclonine works by blocking both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, stabilizing the membrane and inhibiting depolarization. Salbutamol (also known as albuterol) works by relaxing and opening up the airways, making breathing easier and improving symptoms like shortness of breath, chest tightness, and wheezing. This combination may be used for procedures like awake intubation, though some research suggests caution with this specific combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dyclonine + salbutamol.